Developing Eradication Investment Cases for Onchocerciasis, Lymphatic Filariasis, and Human African Trypanosomiasis: Rationale and Main Challenges

PLoS Neglected Tropical Diseases

Volumn 7, Issue 11, 2013, Pages

  Tediosi, Fabrizio ^a,b   Steinmann, Peter ^a,b   de Savigny, Don ^a,b   Tanner, Marcel ^a,b  

^a SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALBENDAZOLE; IVERMECTIN;

AFRICAN TRYPANOSOMIASIS; ARTICLE; COST EFFECTIVENESS ANALYSIS; DISEASE CONTROL; DISEASE ELIMINATION; DISEASE ERADICATION; DISEASE SURVEILLANCE; DISEASE TRANSMISSION; ERADICATION INVESTMENT CASE; GOVERNMENT; HEALTH CARE PRACTICE; HEALTH IMPACT ASSESSMENT; HUMAN; LYMPHATIC FILARIASIS; ONCHOCERCIASIS; SOCIAL ASPECT; SOCIOECONOMICS; ECONOMICS; ELEPHANTIASIS, FILARIAL; HEALTH; TRYPANOSOMIASIS, AFRICAN;

ELEPHANTIASIS, FILARIAL; GLOBAL HEALTH; HUMANS; ONCHOCERCIASIS; TRYPANOSOMIASIS, AFRICAN;

EID: 84888238571     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0002446     Document Type: Article

References (42)

1. Cochi S (2010) Ernst Strüngmann Forum. Disease eradication in the context of global health in the 21st century. Available: http://www.esforum.de/forums/esf07_disease_eradication.html. Accessed 30 May 2013.
2. Cochi S, Dowdle WR (2011) The eradication of infectious diseases. Understanding the lessons and advancing experience. In: Cochi LS, Dowdle WR, editors. Disease eradication in the 21st century: implications for global health. Cambridge, Massachusetts: MIT Press. pp. 1-12.
3. Miller M, Barrett MP (2006) Control and eradication. In: Jamison DT, et al. editors. Disease control priorities in developing countries. Oxford University Press and The World Bank.
4. Eradication ITFfD (2008) Updated table of diseases considered as candidates for global eradication by the ITFDE. Available: http://www.cartercenter.org/resources/pdfs/news/health_publications/itfde/updated_disease_candidate_table.pdf. Accessed 14 October 2013.
5. Walker DG, Lupp J (2011) Guide for preparing an eradication investment case. Available: http://eic-guidelines.org/. Accessed 14 October 2013.
6. Hotez PJ, Molyneux DH, Fenwick A, Kumaresan J, Sachs SE, et al. (2007) Control of neglected tropical diseases. N Engl J Med 357: 1018-1027.
7. Strebel P, Ottesen EA, de Quadros CA, Guirguis S, Hall RG, et al. (2011) Assessing the feasibility of an eradication initiative. In: Cocho LS, Dowdle WR, editors. Disease eradication in the 21st century: implications for global health. Cambridge, Massachusetts: MIT Press. pp. 89.
8. Basáñez M-G, McCarthy JS, French MD, Yang G-J, Walker M, et al. (2012) A research agenda for helminth diseases of humans: modelling for control and elimination. PLoS Negl Trop Dis 6: e1548 doi:10.1371/journal.pntd.0001548.
9. Habbema JD, Alley ES, Plaisier AP, van Oortmarssen GJ, Remme JH, (1992) Epidemiological modelling for onchocerciasis control. Parasitol Today 8: 99-103.
10. Abiose A, Awadzi K (1995) Report of a WHO Expert Committee on onchocerciasis control. Introduction: onchocerciasis and its control. Geneva: World Health Organization.
11. Plaisier AP, van Oortmarssen GJ, Remme JH, Alley ES, Habbema JD, (1991) The risk and dynamics of onchocerciasis recrudescence after cessation of vector control. Bull World Health Organ 69: 169-178.
12. Winnen M, Plaisier AP, Alley ES, Nagelkerke NJ, van Oortmarssen G, et al. (2002) Can ivermectin mass treatments eliminate onchocerciasis in Africa? Bull World Health Organ 80: 384-390.
13. Norman RA, Chan MS, Srividya A, Pani SP, Ramaiah KD, et al. (2000) EPIFIL: the development of an age-structured model for describing the transmission dynamics and control of lymphatic filariasis. Epidemiol Infect 124: 529-541.
14. Stolk WA, de Vlas SJ, Borsboom GJ, Habbema JD, (2008) LYMFASIM, a simulation model for predicting the impact of lymphatic filariasis control: quantification for African villages. Parasitology 135: 1583-1593.
15. Stolk WA, de Vlas SJ, Habbema JD, (2006) Advances and challenges in predicting the impact of lymphatic filariasis elimination programmes by mathematical modelling. Filaria J 5: 5.
16. Gambhir M, Michael E, (2008) Complex ecological dynamics and eradicability of the vector borne macroparasitic disease, lymphatic filariasis. PLoS ONE 3: e2874 doi:10.1371/journal.pone.0002874.
17. Jusot JF, de Vlas SJ, Vanoortmarssen GJ, De Muynck A, (1995) Contribution of a mathematical model in the control of a parasitosis: the case of human African trypanosomiasis due to Trypanosoma brucei gambiense. Ann Soc Belg Med Trop 75: 257-272.
18. Muller G, Grébaut P, Gouteux JP, (2004) An agent-based model of sleeping sickness: simulation trials of a forest focus in southern Cameroon. C R Biol 327: 1-11.
19. Checchi F, Filipe JAN, Haydon DT, Chandramohan D, Chappuis F, (2008) Estimates of the duration of the early and late stage of gambiense sleeping sickness. BMC Infect Dis 8: 16.
20. Checchi F, Filipe JAN, Barrett MP, Chandramohan D, (2008) The natural progression of gambiense sleeping sickness: what is the evidence? PLoS Negl Trop Dis 2: e303 doi:10.1371/journal.pntd.0000303.
21. Gouteux JP, Artzrouni M, (2000) Persistence and resurgence of sleeping sickness caused by Trypanosoma brucei gambiense in historic foci. Biomathematical approach of an epidemiologic enigma. C R Acad Sci III 323: 351-364.
22. Odiit M, Coleman PG, Liu WC, McDermott JJ, Fèvre EM, et al. (2005) Quantifying the level of under-detection of Trypanosoma brucei rhodesiense sleeping sickness cases. Trop Med Int Health 10: 840-849.
23. Murray CJL, Lopez AD (1996) The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Cambridge, Massachusetts: Harvard University Press.
24. World Health Organization (2009) WHO guide to identify the economic consequences of disease and injury. Geneva: World Health Organization. Available: www.who.int/choice/publications/d_economic_impact_guide.pdf. Accessed 30 May 2013.
25. Drummond M, O'Brien BJ, Stoddart GL, Torrance G (1997) Methods for the economic evaluation of health care programmes. New York: Oxford University Press.
26. Gold MR, Gold SR, Weinstein MC (1996) Cost-effectiveness in health and medicine. Oxford: Oxford University Press.
27. Tan-Torres Edejer T, Baltussen R, Adam T, Hutubessy R, Acharya A, et al. (2003) Making choices in health: WHO guide to cost-effectiveness analysis. Geneva: World Health Organization.
28. Muela JR, Hausmann-Muela S (2013) The social aspects of lymphatic filariasis, onchocerciasis and human African trypanosomiasis: a systematic literature review. Basel: Swiss TPH.
29. Van den Berg H, Kelly-Hope LA, Lindsay SW, (2013) Malaria and lymphatic filariasis: the case for integrated vector management. Lancet Infect Dis 13: 89-94.
30. Homeida M, Braide E, Elhassan E, Amazigo UV, Liese B, et al. (2002) APOC's strategy of community-directed treatment with ivermectin (CDTI) and its potential for providing additional health services to the poorest populations. African Programme for Onchocerciasis Control. Ann Trop Med Parasitol 96 Suppl. 1: S93-104.
31. The malERA Consultative Group on Health Systems Operational Research (2011) A research agenda for malaria eradication: health systems and operational research. PLoS Med 8: e1000397 doi:10.1371/journal.pmed.1000397.
32. de Savigny D, Adam T (2009) System thinking for health system strengthening. Geneva: World Health Organization.
33. Adam T, de Savigny D, (2012) Systems thinking for strengthening health systems in LMICs: need for a paradigm shift. Health Policy Plan 27 Suppl 4: iv1-3.
34. Mackenzie CD, Homeida MM, Hopkins AD, Lawrence JC, (2012) Elimination of onchocerciasis from Africa: possible? Trends Parasitol 28: 16-22.
35. Traore MO, Sarr MD, Badji A, Bissan Y, Diawara L, et al. (2012) Proof-of-principle of onchocerciasis elimination with ivermectin treatment in endemic foci in Africa: final results of a study in Mali and Senegal. PLoS Negl Trop Dis 6: e1825 doi:10.1371/journal.pntd.0001825.
36. World Health Organization (2010) Lymphatic filariasis- progress report 2000-2009 and strategic plan 2010-2020 of the global programme to eliminate lymphatic filariasis: halfway towards eliminating lymphatic filariasis. Geneva: World Health Organization.
37. World Health Organization (2012) Global programme to eliminate lymphatic filariasis: progress report, 2011. Wkly Epidemiol Rec 37: 345-356.
38. Michael E, Malecela-Lazaro MN, Kazura JW, (2007) Epidemiological modelling for monitoring and evaluation of lymphatic filariasis control. Adv Parasitol 65: 191-237.
39. Esterre P, Plichart C, Sechan Y, Nguyen NL, (2001) The impact of 34 years of massive DEC chemotherapy on Wuchereria bancrofti infection and transmission: the Maupiti cohort. Trop Med Int Health 6: 190-195.
40. Bockarie MJ, Pedersen EM, White GB, Michael E, (2009) Role of vector control in the global program to eliminate lymphatic filariasis. Annu Rev Entomol 54: 469-487.
41. Simarro PP, Franco JR, Diarra A, Ruiz Postigo JA, Jannin J, (2013) Diversity of human African trypanosomiasis epidemiological settings requires fine-tuning control strategies to facilitate disease elimination. Res Rep Trop Med 4: 1-6.
42. Welburn SC, Maudlin I, Simarro PP, (2009) Controlling sleeping sickness- a review. Parasitology 136: 1943-1949.